Ionis Pharmaceuticals, Inc. has licensed IONIS-DNM2-2.5Rx, a drug that treats centronuclear myopathy (CNM), to Dynacure. 

Ionis earned a $5 million license fee in the form of Dynacure equity from the agreement, and is eligible to receive additional cash or equity of up to more than $205 million in milestone payments. They also now have the eligibility to receive royalties on future product sales of the drug.

The collaboration also means that Dynacure will now assume all development and commercialization responsibilities for the program. 

“This development puts us one step closer to potentially finding a new treatment for patients suffering with CNM, a devastating disease with no adequate treatments” said Stephane van Rooijen, chief executive officer of Dynacure.